METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    2.
    发明申请
    METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER 失效
    治疗癌症的方法和组合

    公开(公告)号:US20100120685A1

    公开(公告)日:2010-05-13

    申请号:US12598240

    申请日:2008-04-30

    申请人: Guojun Bu

    发明人: Guojun Bu

    CPC分类号: A61K38/17

    摘要: Oligopeptides which can be used to treat cancer are disclosed. Further disclosed are methods of treating cancer, including breast cancer, skin cancer, prostate cancer and multiple myeloma (MM). These methods include administration of a polypeptide encoded by the Mesd gene, or an oligopeptide comprising a contiguous subsequence of a Mesd polypeptide.

    摘要翻译: 公开了可用于治疗癌症的寡肽。 进一步公开的是治疗癌症的方法,包括乳腺癌,皮肤癌,前列腺癌和多发性骨髓瘤(MM)。 这些方法包括施用由Mesd基因编码的多肽,或包含Mesd多肽的连续子序列的寡肽。

    Methods and compositions for the treatment of cancer
    3.
    发明授权
    Methods and compositions for the treatment of cancer 失效
    用于治疗癌症的方法和组合物

    公开(公告)号:US08198236B2

    公开(公告)日:2012-06-12

    申请号:US12598240

    申请日:2008-04-30

    申请人: Guojun Bu

    发明人: Guojun Bu

    IPC分类号: A61K38/00 A61K38/08

    CPC分类号: A61K38/17

    摘要: Oligopeptides which can be used to treat cancer are disclosed. Further disclosed are methods of treating cancer, including breast cancer, skin cancer, prostate cancer and multiple myeloma (MM). These methods include administration of a polypeptide encoded by the Mesd gene, or an oligopeptide comprising a contiguous subsequence of a Mesd polypeptide.

    摘要翻译: 公开了可用于治疗癌症的寡肽。 进一步公开的是治疗癌症的方法,包括乳腺癌,皮肤癌,前列腺癌和多发性骨髓瘤(MM)。 这些方法包括施用由Mesd基因编码的多肽,或包含Mesd多肽的连续子序列的寡肽。

    Oligopeptides for treatment of osteoporosis and other bone diseases and methods therefor
    4.
    发明申请
    Oligopeptides for treatment of osteoporosis and other bone diseases and methods therefor 审中-公开
    用于治疗骨质疏松症和其他骨病的寡肽及其方法

    公开(公告)号:US20100055712A1

    公开(公告)日:2010-03-04

    申请号:US12459060

    申请日:2009-06-26

    申请人: Guojun Bu

    发明人: Guojun Bu

    IPC分类号: G01N33/53

    摘要: Methods of identifying compounds for treating Alzheimer's disease are disclosed. These methods comprise a) forming an in vitro mixture comprising i) cells expressing LDL receptor related protein 1 (LRP1), ii) an LRP1 ligand comprising a label, and iii) a candidate compound; and b) determining quantity of the label incorporated by the cells, whereby a candidate compound is deemed effective for treating Alzheimer's disease if the quantity of label incorporated by the cells exceeds that of a control in vitro mixture comprising cells expressing LRP1 and the LRP1 ligand, but not comprising the compound.

    摘要翻译: 公开了鉴定用于治疗阿尔茨海默病的化合物的方法。 这些方法包括a)形成体外混合物,其包含i)表达LDL受体相关蛋白1(LRP1)的细胞,ii)包含标记的LRP1配体,和iii)候选化合物; 和b)确定由细胞掺入的标记物的量,其中如果细胞掺入的标记量超过包含表达LRP1和LRP1配体的细胞的对照体外混合物的量,则将候选化合物视为有效治疗阿尔茨海默氏病, 但不包含该化合物。

    Methods and compositions for inhibition of hepatic clearance of
tissue-type plasminogen activator
    5.
    发明授权
    Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator 失效
    抑制组织型纤溶酶原激活物肝清除的方法和组合物

    公开(公告)号:US5474766A

    公开(公告)日:1995-12-12

    申请号:US992827

    申请日:1992-12-18

    摘要: Methods and compositions for inhibiting the hepatic clearance of tissue-type plasminogen activator (t-PA) in vivo by administering a t-PA-hepatic clearance-inhibiting amount of 39 kDa protein or a t-PA-hepatic clearance-inhibiting fragment thereof, or genetically or chemically modified forms of the 39 kDa protein or fragments thereof are described. Methods and compositions for treatment of thrombolytic diseases by administering t-PA and a t-PA-hepatic clearance-inhibiting effective amount of 39 kDa protein, a t-PA-hepatic clearance inhibiting fragment thereof, and genetically or chemically modified forms of the 39 kDa protein or its fragments are described.

    摘要翻译: 通过施用t-PA-肝清除抑制量的39kDa蛋白质或其t-PA-肝脏清除抑制片段,在体内抑制组织型纤溶酶原激活物(t-PA)的肝清除的方法和组合物, 或遗传或化学修饰形式的39kDa蛋白质或其片段。 用于治疗溶栓性疾病的方法和组合物,通过施用t-PA和t-PA-肝清除抑制有效量的39kDa蛋白质,其t-PA-肝脏清除抑制片段,以及遗传或化学修饰形式的39 描述了kDa蛋白或其片段。